TP方案及FP方案同步调强放疗治疗中晚期食管癌的临床疗效评价  

Study on the Clinical Efficacy of TP and FP Regimen Concurrent Intensity Modulated Radiotherapy for Adcanced Esophageal Cancer.

作　　者：姜兆祥 王忠超 李倩 翟韦玉 田浩 

机构地区：[1]新沂市人民医院肿瘤放疗科,江苏新沂221400

出　　处：《黑龙江医药》2015年第4期952-954,共3页Heilongjiang Medicine journal

摘　　要：目的:观察TP方案及FP方案同步调强放疗治疗中晚期食管癌的临床疗效和毒副反应。方法:中晚期食管癌患者80例随机分成两组,每组40例。研究组:紫杉醇+顺铂(TP方案)化疗同步调强放疗;对照组:5氟尿嘧啶+顺铂(FP方案)化疗同步调强放疗,比较两组临床疗效,1、2年生存期及毒副反应。结果:研究组和对照组临床有效率分别为72.5%,47.5%;远处转移率分别为17.5%和37.5%;研究组和对照组1、2年生存期分别为80.0%、57.5%,62.5%、40.0%;研究组放射性肺炎发生率稍高于对照组。结论:紫杉醇联合顺铂同步调强放疗可以提高中晚期食管癌患者的临床有效率,降低远处转移控制率,毒副作用可耐受。Objective： To observe the efficacy and safety of TP regimen and FP concurrent Intensity modulated radiothera- py （IMRT） in the treatment of advanced esophageal cancer. Methods：Eighty patients with advanced esophageal cancer were randomly divided into two groups, 40 cases in each group Study group was given paclitaxel plus cisplatin chemotherapy （TP regimen） concurrent IMRT, the contrast was given 5-fluoro- uracil plus cisplatin chemotherapy （FP regimen） combined with IMRT.The clinical efficacy, 1 and 2-year survival rates as well as toxic reactions were compared in both groups. Results：The response rate of the study group and contrast group were 72.5% vs 47.5% （P〈0.05） and the rate of distant metastasis were 17.5% vs 37.5% （P〈0.05）respectively, 1 and 2-year survival rates were 80.0%, 57.5% vs 62.5% ,40.0%（P〉0.05）, The inci- dence of radiation pneumonotis was slightly higher in the study group than contrast group. Conclusion：paclitaxel plus cisplatin chemotherapy concurrent IMRT can improve the clinical efficacy and reduce the rate of distant metastasis of patients with ad- vanced esophageal cancer, and the toxic reactions can he tolerated.

关 键 词：中晚期食管癌 调强放疗 化疗 

分 类 号：R735.1[医药卫生—肿瘤]